The calpain inhibitor, A-705253, corrects penile nitrergic nerve dysfunction in diabetic mice

European Journal of Pharmacology

Volumn 538, Issue 1-3, 2006, Pages 148-153

  Nangle, Matthew R ^a   Cotter, Mary A ^a   Cameron, Norman E ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Calpain; Corpus cavernosum; Diabetes; Endothelium; Erectile dysfunction; Neuropathy; Nitric oxide; Smooth muscle

Indexed keywords

A 705253; ACETYLCHOLINE; CALPASTATIN; N (1 BENZYL 2 CARBAMOYL 2 OXOETHYL) 2 [(4 DIETHYLAMINOMETHYLPHENYL)ETHEN 1 YL]BENZAMIDE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; STREPTOZOCIN; UNCLASSIFIED DRUG;

ADRENERGIC NERVE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTONOMIC NEUROPATHY; CONTROLLED STUDY; CORPUS CAVERNOSUM; DIABETES MELLITUS; DIABETIC NEUROPATHY; ELECTROSTIMULATION; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; MALE; MOUSE; MUSCLE CONTRACTION; MUSCLE RELAXATION; MUSCLE TONE; NERVE FUNCTION; NEUROLOGIC DISEASE; NITRERGIC NERVE; NONHUMAN; PENIS; PRIORITY JOURNAL; STREPTOZOCIN DIABETES;

ACETYLCHOLINE; ANIMALS; BENZAMIDES; BLOOD GLUCOSE; BODY WEIGHT; CALPAIN; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; MALE; MICE; MUSCLE RELAXATION; MUSCLE, SMOOTH, VASCULAR; NITRERGIC NEURONS; NITROPRUSSIDE; ORGAN SIZE; PENIS; PHENYLEPHRINE; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS;

EID: 33646524709     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.03.068     Document Type: Article

References (32)

1. Araujo I.M., Verdasca M.J., Leal E.C., Bahr B.A., Ambrosio A.F., Carvalho A.P., and Carvalho C.M. Early calpain-mediated proteolysis following AMPA receptor activation compromises neuronal survival in cultured hippocampal neurons. J. Neurochem. 91 (2004) 1322-1331
2. Azadzoi K.M., and de Tejada I.S. Diabetes mellitus impairs neurogenic and endothelium-dependent relaxation of rabbit corpus cavernosum smooth muscle. J. Urol. 148 (1992) 1587-1591
3. Bayraktutan U. Free radicals, diabetes and endothelial dysfunction. Diabetes Obes. Metab. 4 (2002) 224-238
4. Bender A.T., Silverstein A.M., Demady D.R., Kanelakis K.C., Noguchi S., Pratt W.B., and Osawa Y. Neuronal nitric-oxide synthase is regulated by the Hsp90-based chaperone system in vivo. J. Biol. Chem. 15 (1999) 1472-1478
5. Branca D. Calpain-related diseases. Biochem. Biophys. Res. Commun. 322 (2004) 1098-1104
6. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414 (2001) 813-820
7. Cameron N.E., and Cotter M.A. Diabetes causes an early reduction in autonomic ganglion blood flow in rats. J. Diabetes Complicat. 15 (2001) 198-202
8. Cameron N.E., Eaton S.E.M., Cotter M.A., and Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 44 (2001) 1973-1988
9. Cellek S., Foxwell N.A., and Moncada S. Two phases of nitrergic neuropathy in streptozotocin-induced diabetic rats. Diabetes 52 (2003) 2353-2362
10. Cox N.J., Hayes M.G., Roe C.A., Tsuchiya T., and Bell G.I. Linkage of calpain 10 to type 2 diabetes: the biological rationale. Diabetes 53 Suppl. 1 (2004) S19-S25
11. de Tejada I.S., Goldstein I., Azadzoi K.M., Krane R.J., and Cohen R.A. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N. Engl. J. Med. 320 (1989) 1025-1030
12. Garcia-Cardena G., Fan R., Shah V., Sorrentino R., Cirino G., Papapetropoulos A., and Sessa W.C. Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature 392 (1998) 821-824
13. Giuliano F., and Rampin O. Neural control of erection. Physiol. Behav. 83 (2004) 189-201
14. Gocmen C., Secilmis A., Kumcu E.K., Ertug P.U., Onder S., Dikmen A., and Baysal F. Effects of vitamin E and sodium selenate on neurogenic and endothelial relaxation of corpus cavernosum in the diabetic mouse. Eur. J. Pharmacol. 398 (2000) 93-98
15. Harris F., Chatfield L., Singh J., and Phoenix D.A. Role of calpains in diabetes mellitus: a mini review. Mol. Cell. Biochem. 261 (2004) 161-167
16. Horikawa Y., Oda N., Cox N.J., Li X., Orho-Melander M., Hara M., Hinokio Y., Lindner T.H., Mashima H., Schwarz P.E., del Bosque-Plata L., Horikawa Y., Oda Y., Yoshiuchi I., Colilla S., Polonsky K.S., Wei S., Concannon P., Iwasaki N., Schulze J., Baier L.J., Bogardus C., Groop L., Boerwinkle E., Hanis C.L., and Bell G.I. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nature Genet. 26 (2000) 163-175
17. Keegan A., Cotter M.A., and Cameron N.E. Effects of diabetes and treatment with the antioxidant, α-lipoic acid, on endothelial and neurogenic functions of corpus cavernosum in rats. Diabetologia 42 (1999) 343-350
18. Kieran D., and Greensmith L. Inhibition of calpains, by treatment with leupeptin, improves motoneuron survival and muscle function in models of motoneuron degeneration. Neuroscience 125 (2004) 427-439
19. Levy J., Gavin J.R., and Sowers J.R. Diabetes mellitus: a disease of abnormal cellular calcium metabolism?. Am. J. Med. 3 (1994) 260-273
20. Lin L.-Y., Lin C.-Y., Ho F.-M., and Liau C.S. Up-regulation of the association between heat shock protein 90 and endothelial nitric oxide synthase prevents high glucose-induced apoptosis in human endothelial cells. J. Cell. Biochem. 94 (2005) 194-201
21. Lubisch W., Beckenbach E., Bopp S., Hofmann H.-P., Kartal A., Kästel C., Lindner T., Metz-Garrecht M., Reeb J., Regner F., Vierling M., and Möller A. Benzoylalanine-derived ketomides carrying vinylbenzyl amino residues: discovery of potent water-soluble calpain inhibitors with oral bioavailability. J. Med. Chem. 46 (2003) 2404-2412
22. Nangle M.R., Cotter M.A., and Cameron N.E. Effects of rosuvastatin on nitric oxide-dependent function in aorta and corpus cavernosum of diabetic mice: relationship to cholesterol biosynthesis pathway inhibition and lipid lowering. Diabetes 52 (2003) 2396-2402
23. Nangle M.R., Cotter M.A., and Cameron N.E. Effects of the peroxynitrite decomposition catalyst, FeTMPyP, on function of corpus cavernosum from diabetic mice. Eur. J. Pharmacol. 502 (2004) 143-148
24. Neuhof C., Fabiunke V., Deibele K., Speth M., Moller A., Lubisch W., Fritz H., Tillmanns H., and Neuhof H. Reduction of myocardial infarction by calpain inhibitors A-705239 and A-705253 in isolated perfused rabbit hearts. Biol. Chem. 385 (2004) 1077-1082
25. Sandmann S., Prenzel F., Shaw L., Schauer R., and Unger T. Activity of calpains I and II in chronically infracted rat myocardium - influence of the calpain inhibitor CAL 9961. Br. J. Pharmacol. 135 (2002) 1951-1958
26. Shore A.C., Evans J.C., Frayling T.M., Clark P.M., Lee B.C., Horikawa Y., Hattersley A.T., and Tooke J.E. Association of calpain-10 gene with microvascular function. Diabetologia 45 (2002) 899-904
27. 2+/calmodulin binding. Biochem. J. 355 (2001) 357-360
28. Sreenan S.K., Zhou Y.-P., Otani K., Hansen P.A., Currie K.P.M., Pan C.-Y., Lee J.-P., Ostrega D.M., Pugh W., Horikawa Y., Cox N.J., Hanis C.L., Burant C.F., Fox A.P., Bell G.I., and Polonsky K.S. Calpains play a role in insulin secretion and action. Diabetes 50 (2001) 2013-2020
29. Stalker T.J., Skvarka C.B., and Scalia R. A novel role for calpains in the endothelial dysfunction of hyperglycaemia. Fed. Am. Soc. Exp. Biol. J. 17 (2003) 1511-1513
30. Stalker T.J., Gong Y., and Scalia R. The calcium-dependent protease calpain causes endothelial dysfunction in type 2 diabetes. Diabetes 54 (2005) 1132-1140
31. Thompson C.S., Mumtaz F.H., Khan M.A., Wallis R.M., Mikhailidis D.P., Morgan R.J., Angelini G.D., and Jeremy J.Y. The effect of sildenafil on corpus cavernosum smooth muscle relaxation and cyclic GMP formation in the diabetic rabbit. Eur. J. Pharmacol. 425 (2001) 57-64
32. van Etten R.W., de Koning E.J., Honing M.L., Stroes E.S., Gaillard C.A., and Rabelink T.J. Intensive lipid lowering by statin therapy does not improve vascular reactivity in patients with type 2 diabetes. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 799-804